Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cynthia McMurray
University of Calif Lawrenc Berkeley Lab, Department: Genetics
Should you be removed from our database? Contact us at [email protected]. Read more below.
Solano Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The institution concluded that Dr. McMurray's financial interest in Solano Pharmaceuticals represents a Financial Conflict of Interest because the work conducted in the 274003-Collaboration "Chemical Fingerprinting..." may provide specific knowledge about the efficacy, or lack thereof, of the compound Solano Pharmaceuticals is developing as a chemical therapeutic. At a high level, the work done by Solano Pharmaceuticals aims to commercialize one element of the basic research performed in the 274003-Collaboration.
In this grant, the investigator's research focuses on refinement of diagnostic tools for certain brain diseases, and that knowledge could have some impact on the company's development of therapeutics to treat those same diseases.
Solano Pharmaceutical's work is to test ADME for new chemical derivatives of XJB-5-131 with a goal of developing new derivatives of XJB-5-131 for medicinal chemistry.
Metabolic markers for mitochondrial function
PROJECT NARRATIVE Mitochondrial dysfunction is a factor in numerous chronic diseases and environmental exposures, but early deficits in MT function are difficult to detect. To address this problem, we have developed and applied a new technology for single cell mass spectrometry, called NIMS. NIMS has both single cell resolution and the high sensitivity needed to detect early biomarkers of MT dysfunction, and will be used to define 'signatures' of early MT dysfunction in single cells. Thus, NIMS technology reduces system heterogeneity, has the high sensitivity needed for detecting meaningful metabolic markers of early MT decline, and the ability to spatially assign signatures in distinct cell types. We apply NIMS identify the effects of oxidative damage in the brain, blood and urine in animal models.
Filed on June 22, 2016.
Tell us what you know about Cynthia McMurray's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Cynthia McMurray filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Cynthia McMurray | University of Calif Lawrenc Berkeley Lab | Conflict of Interest | Solano Pharmaceuticals | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.